Modern management of diabetes in cardiology: Impact of SGLT2 inhibition on cardiovascular outcomes and heart failureAug. 27, 2017 - ESC, Barcelona, Spain
Monday, August 28, 2017
- Introduction -David Fitchett, MD - Toronto, Canada
- SGLT2 inhibition in cardiology: What a cardiologists needs to know? - Naveed Sattar, MD -Glasgow, United Kingdom
- Management of CV Risk & T2DM: Implications of novel outcome trials - John Deanfield, MD - London, United Kingdom
- Heart failure & Diabetes: Time for a more unified approach - Stefan Anker, MD - Gottingen, Germany
The Educational objectives are to:
- Summarise the epidemiology and pathophysiology of patients at increased cardiovascular risk and diabetes
- Identify key components of renal glucose handling and the contribution of the kidney to glucose homeostasis
- Describe the effect of multiple interventions that currently are deployed for T2D on cardiovascular safety and the currently unmet need on impacting cardiovascular outcomes
- Explain, based on scientific evidence, the effects that SGLT2 inhibiting agents may have on cardiometabolic markers, including lipids, weight gain, risk of hypoglycemia, HbA1c, glucose levels, related markers and cardiovascular outcomes
- Discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multi-risk patients
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
In compliance with EBAC guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities
Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.
Please pre-register if you wish to attend the symposium. All participants should be registered for the ESC 2017 congress via the ESC